Meeting
2014 ASCO Annual Meeting
Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
Authors
Siraj M. Ali
Foundation Medicine, Inc., Cambridge, MA
Siraj M. Ali , Sai-Hong Ignatius Ou , Jie He , Nir Peled , Juliann Chmielecki , Mary Colleen Pinder , Norma Alonzo Palma , Wallace L. Akerley , Kai Wang , Julian R. Molina , Jeffrey S. Ross , Roman Yelensky , Garrett Michael Frampton , Lyudmila Bazhenova , Gary A. Palmer , Deborah Morosini , Doron Lipson , Phil Stephens , Ravi Salgia , Vincent A. Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8049)
DOI
10.1200/jco.2014.32.15_suppl.8049
Abstract #
8049
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).
First Author: Jeffrey S. Ross
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2016 ASCO Annual Meeting
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
First Author: Daniel Shao-Weng Tan